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necrosis leading to a cardiomyopathy with feature of hibernation. Early chemokine induc- 
tion and interstitial fibrosis due to frequent sublethal ischemic episodes may have a role 
in mediating left ventricular dysfunction in ischemic cardiomyopathy. 
4:15 p.m. 
836-2 Serum Levels of Unbound Free Fatty Acids Reveal High 
Sens i t iv i ty  for Early Detection of Acute Myocardial 
Infarction in Patient Samples From the TIMI II Trial 
Alan M. Kleinfeld. Kevin J. Kleinfeld, Jesse E. Adams, lIP, TarreyPines Institute for 
Molecular Studies, San Diego, California, Jewish Hospital, Louisville, Kentucky. 
Background: Levels of unbound free fatty acids (FFAu) have been found to increase with 
myocardial cellular ischemia in patients undergoing balloon angioplasty (Kleinfeld et al, 
Am J Cardiol 1996;78:1350). To assess whether FFAu are an effective marker of 
ischemia in acute myocardial infarction (AMI), levels of FFAu were determined in serum 
samples from patients enrolled in the TIMI tl trial (TIMI Study Group, N Engl J Med 
1989;320:618). Methods: Patients in this trial were treated with tissue plasminogen acti- 
vator (topA) for AMI. Blood samples were drawn upon presentation, and then 50 minutes, 
5 h and 8 h after t-PA. These samples have been maintained at -70°C by the National 
Heart Lung Blood Institute. FFAu measurements and partial data analysis has been com- 
pleted on 458 patients (75 F, 383 M). Measurements were done at 22°C using the 
ADIFAB2 (Richieri et al, J Biol Chem 1996;271:11291) fluorescent probe of FFAu 
(healthy controls = 2.6 ± 0.6 nM). Results: FFAu values for the TIMI patients ranged from 
2 to 5000 nM. Average values and standard deviations for each of the 4 blood draws, 
from time of admission to 8 h were: 13 ± 17, 22 ± 25, 11 ± 13, and 10 ± 11 (nM). These 
results indicate, relative to the control population, an approximately 4 fold increase upon 
admission, a further 2 fold increase following t-PA with a gradual decrease within 5 h of t- 
PA. Using a 5 nM cutoff, the predicted sensitivity for detection of AMI was 91% using 
samples at time of admission only, and 98% using time of admission and the 50 minute 
sample. Only 19 % of patients had elevated levels of creatine kinase on admission. 
Specificity was estimated as 93% by comparison with a distribution that includes healthy 
individuals plus patients with non cardiovascular diseases. FFAu values for samples 
drawn at presentation were found to be highly (p<0.025) correlated with mortality; an 
increase of 4 fold in mortality rate is predicted from lowest to highest FFAu levels. Con- 
clusions: These data indicate that levels of FFAu are: 1) a sensitive indicator of ischemia 
in AMI, 2) elevated well before markers of cardiac necrosis, 3) an indictor of reperfusion 
therapy, and 4) a predictor of mortality in these patients. 
4:30 p.m. 
836-3 A Cardioprotective Agent, JTV519, Inhibits Apoptotic 
Cell Death of Postischemic Reperfused Myocardium 
Through _PKC-Medlated ERK Activation 
Hirovuki Takenaka, Yasuki Kihara, Koichi Inagaki, Takeshi Yoneda, Department of 
Cardiovascular Medicine, Kyoto Universi~ Kyoto, Japan. 
Objective: JTV519 (JTV), a 1,4-benzothiazepine derivative, confers cardioprotective 
effects on the post-ischemic, reperfused myocardium through a specific activation of 8-iso- 
form of protein kinase C (PKC) (Inagaki et al., Circulation, 2000). In this study, we further 
tested the hypothesis whether the downstream of ~-PKC activation may link to its inhibitory 
effects on the apoptotic cell death. Methods: Hearts were isolated from male SD rats (n=7, 
for each group), and were coronary-berfused in a Langendodf setup at a constant coronary 
flow under electrical pacing at 3.33Hz. The preparation was treated with lpM JTV or vehi- 
cle for 5 min, and then subjected to a 30-min global ischemia and the subsequent 60-min 
full reperfusion protocol, On the other hand, isolated ventricular myocytes from neonatal 
rats (n--6, for each group) were treated with J'IV or vehicle before an exposure to 50HM 
H202 for 80 rain. Both the heart and cell preparations were subjected to TUNEL staining, 
DNA fragmentation assay, and immunoblotting for phosphorylated forms of JNK, ERK1/2, 
and p38-MAPK. Results: In the reperfused heart preparations, JTV ameliorated the recov- 
ery of left ventdcuJar developed pressure by 80% (p<0,01), which was associated with a 
reduction of TUNEL-positive ventricular myocytes by 10% (p<0.05). in isolated cells, JTV 
reduced the H202-induced TUNEL staining from 43% to 30% (p<0.05). JTV also showed 
substantial decreases of DNA fragmentation in beth preparations. These anti-apoptotic 
effects of JTV were inhibited either by GF109203X (GF, a PKC inhibitor) or by PD98059 
(PD, a MEK inhibitor), In the cell preparations, JTV further increased H202-induced phos- 
phorylation of ERKs by 55% (p<0.01). This ERK activation was decreased by pretreating 
the system with 50~M PD, 5HM GF, and I~M rottlerin(a ~-PKC specific inhibitor) to the lev- 
els of 18.0%, 55.2%, and 31.5%, respectively (p<O,05). JTV did not show significant effects 
on JNK and p38-MAPK phosphorylation. Conclusion: JTV519 protects the post-ischemic 
reperfused myocytes from the apoptotic cell death through a specific activation of the 5- 
PKC/ERK cascade. 
4:45 p.rn, 
836-4 Hearts of Stat 6 Knockout Mice Are Resistant to 
Ischemla Reperfusion In jury  
Genbu Yamaura. Shoji Fukoda, Kazuhisa Kishima, Jianhua Cui, Richard M. Engelman, 
Dipak K. Das, University of Connecticut Medical Center, Farmington, Connecticut. 
Background: STATs (Signal transducers and Activators of Transcription) comprise a fam- 
ily of transcription factors that reside in the cytoplasm of resting cells. Recently, isohemia/ 
raperfusion was found to rapidly activate JAK (a group of tyrosine kinases)/STAT signal- 
ing pathway which play a crucial role in myocardial ischemic injury. Specifically, JAK2 
and STAT 6 were activated even after 15 min ischemia and remained activated during 
subsequent repertusion. 
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Methods: To confirm the role of STAT 6 in ischemic injury, we examined if STAT 6 knock- 
out mice devoid of any copies of STAT 6 gene was resistant to ischemio injury. STAT 6 
knockout mice (n=10) and control wild-type mice (n=10) were anesthetized with pento- 
barbital, hearts excized, and perfused via working mode with KI-IB buffer. The working 
mouse hearts were made globally ischemio for 25 min followed by 2 h of repertusion. Left 
ventricular function was monitored at the baseline and during post-ventricular eperfusion 
and infarct size was determined at the end of the reperfusion. 
Results: Heart rates of the STAT 6 knockout (KO) mice were lower compared to wild-type 
(WT) mice at baseline and at 15 min of repeffusion (15R). Knockout mouse hearts dis- 
played significantty better (p<0.05) post-ischemic ventricular recovery as evidence by 
higher left ventricular pressure (LVP) (mm Hg) [BL: 86.5±0.7 (WT) vs. 97.3±1.7 (KO); 
15R: 75.2±1.4 (WT) vs. 82.2±2 (KO); 30R: 71.8±1.4 (wr) vs. 77.8±2.1 (KO)]; higher dp/ 
dtmax (mm Hg/sec) [BL: 4518±76 (WT) vs. 5085±120; 15R:3807±130 (WT) vs. 
4288±134 (KO); 30R: 3529±131 (W-F) vs. 4026±133 (KO). Infarct size determined by 
~'C  staining was lower in STAT 6 KO mouse hearts (41.1±1.6%) compared to those for 
the WT mice (48.6±2.3%). 
Conclusion: The results of this study demonstrate that hearts of STAT 6 knockout mice 
are resistant to ischemia/repedusion injury suggesting a role of STAT 6 gene in the medi- 
ation of cardiac injury. 
5:00 p.m. 
836-5 Glucagon-Like Peptide-1 (GLP-1) L imi ts  Myocardial 
Stunning Following Acute Coronary Occlusion and 
Reperfusion in Conscious Canines 
Lazaros A. Nikolaidis. Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee 
ZoureUas, Carol Stalarski, Dariush Elahi, Richard P. Shannon, AI/egheny Genera/ 
Hoapita/, Pittsburgh, Pennsy/vania, Massachusetts Genera/Hoapita/, Boston, 
Massachusetts. 
Background: Myocardial ischemia is associated with increased glucose utilization. Glu- 
cose insulin K+ infusion has been shown to improve outcomes. We hypothesized that 
the insulinotropio peptide GLP-1 facilitates recovery of post-ischemic contractile dysfunc- 
tion (stunning). 
Methods: We studied 13 conscious dogs, instrumented with LV pressure gauges, aortic 
and coronary flow (CBF) probes, piezoelectric crystats to measure regional systolic wall 
thickening (W'rh) and a hydraulic coronary artery occluder. All dogs underwent a 10 min 
coronary occlusion (CAO) followed by reperfusion (CAR). Five dogs received a 24-hr 
infusion of GLP-1 (1.5 pmolokg'l-min "1) initiated 1 rain prior to CAR; 8 dogs received pla- 
cebo. We obtained serial recordings tar the first 3 hrs and at 24-hr post-CAR, 
Reaults: Hemodynamic responses and global LV function during CAO and CAR were 
similar in the two groups. Baseline regional W'rh (2.6+_0.3mm) and initial hyperemio 
responses were similar. Despite comparable changes in CBF, GLP-1 treated dogs dem- 
onstrated significantly (*p<0.01) ~ess post-ischemic contractile dysfunction. The salutary 
effects of GLP-1 were sustained for 24-hrs. 
Regional CBF (ml )  Regional WTh (% baseline) 
Control GLP-1 Control GLP-1 
Baseline 21+_1 20+_2 100% 100% 
CAO 3+~ 5+~2 12+8% 16_+11% 
CAR-1 min 113+-9 93+11 76_+6% 84+8% 
5 min 49_+8 41_+9 60+-4% 81_+4%* 
10 rain 22_+2 18_+2 57_+5% 84_+2%* 
15 rain 18_+1 17:~2. 57+5% 87_+2%* 
30 min 19_+2 19.+..2 60+-6% 86_+3%* 
1 hr 17_+1 18_+3 69+-5% 97_+3% ° 
2 hr 17_+2 18:1:2 70-+5% 97_+3%* 
3 hr 17+~ 17_+3 76_+6% 98_+2%* 
24 hr 22.+.2 22~_1 78_+4% 98_+4%* 
Conclusions: When administered at the time of repedusion, GLP-1 limits myocardial 
stunning following brief coronary occlusion. The salutary outcome is sustained for at 
least 24 hrs. GLP-1 may be a promising adjuvant herapy in post-ischemic myocardial 
dysfunction. 
5:15 p.m. 
836-6 Cardiac Serum Marker Release After Percutaneous 
Transluminal Septal Myocardial Ablation: A Human 
Model 
Patricia A. Gum, Steven R. SteinhubL Harry M. Lever, E Van Lente, E. Murat Tuzcu, A. 
Michael Lincoff, The C/eve/and Clinic Foundation, C/eve/and, Ohio. 
Background. Multiple cardiac serum markers are available for determining myocardial cell 
death, but the comparative kinetics of these markers in humans have not yet been fully 
described due to the inability to precisely correlate symptom onset with vessel closure. Per- 
cutaneous transluminal septal myocardial ablation (PTMSA) for hypertrophic obstructive 
cardiomyopathy permits a unique opportunity to identify the time of vessel closure in a 
series Of patients experiencing a MI and compare the course of cardiac serum marker eleo 
vation. 
Methods. We obtained bleed samples every 2 hrs for 48 hrs from t l  pts after PTMSA and 
measured the serum markers: creatine kinase MB (CK MB)(normal 0.0-8.8 ng/ml), myoglo- 
bin (30-90 mg/L), troponin-I (0.0-2.0 ng/ml), and troponin-T (0.0-0.1 ng/ml). 
Results. Mean marker values are displayed in the figure below. In all patients studied, all 
markers were elevated above normal by 2 hrs after vessel closure. Mean peak measure- 
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ments occurred at the following time-points: CK MB 14 hrs, myoglobin 8 hrs, troponin-T and 
troponin-116 hrs. Only myoglobin fell to normal within 48 hrs. 
Conclusion. This is the first human study to track the time course of cardiac serum marker 
release following a MI when the precise timing of vessel closure was known. Our results are 
consistent with previous human studies of marker elevation after MI symptom onset. There- 
fore, symptom onset appears to be a reliable surrogate for vessel closure in an acute MI. 
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disease with 1500 to 2000 patient admissions per year. 
Methods: We retrospectively reviewed charts of patients with ICD-9 codes (International 
Classification of Disease, 9th Revision) for HIV disease and acute coronary syndromes 
at our hospital between January 1996 and December 2000. Fifty patients with either 
unstable angina or myocardial infarction were identified. This represented approximately 
0.6% of all HIV patient admissions during that time period. 
Results: Of the standard cardiovascular dsk factors, one or more were present in 88% of 
the patients and only 5 patients were recently using cocaine. Forty-five (90%) of the 
patients were men and the mean age was 49 + 9 years. The average duration since diag- 
nosis of HIV infection was 7.8 _+ 4.7 years, the average CD4 count was 426 + 290 x 103 
and twenty-nine (58%) were taking protease inhibitors. Forty-five (90%) underwent car- 
diac catheterization during admission and 40 had significant (>50% diameter stenosis) 
coronary artery disease (42% with 1-vessel disease). Patients with (n=21) or without pro- 
tease inhibitor (n=29) use were not significantly different in clinical, demographic or 
angiographic characteristics. Twenty-five (50%) underwent percutaneous coronary inter- 
vention and 9 (18%) other patients had a coronary artery bypass graft surgery with an 
overall in-hospital mortality of 2.9% (0% in percutaneous coronary intervention). 
Conclusion: In a large population of patients with HIV disease, admission for acute cor- 
onary syndromes is uncommon. This descriptive study indicates that nearly all have one 
or more traditional risk factors. Peroutaneous coronary intervention or coronary artery 
bypass graft surgery cna be done safely with a low in-hospital mortality. Controlled, pro- 
spective data are required to assess if there is any direct association between HIV dis- 
ease and acute coronary syndromes. 
9:00 a.m. 
ORAL  CONTRIBUTIONS 
840 Etiological Entit ies as Predictors of Risk 
in Acute  Coronary Syndromes 
Tuesday, March 19, 2002, 8:30 a.m.-lO:O0 a.m. 
Georgia World Congress Center, Hall D1 
8:30 a.m. 
840-1 Nonwhite Race Is Associated With a Higher Rate of 
Death and Ischemic Complications in Patients With 
Acute Coronary Syndromes Despite Modern Early 
Invasive Treatment 
Marc S. Sabatine. Gavin J. Blake, Mark H. Drazner, David A. Morrow, Laura A. 
Demopoulos, Peter M. DiBattiste, Carolyn H. McCabe, Christopher P. Cannon, Eugene 
Braunwald, Brigham and Women's Hospital Boston, Massachusetts. 
Background: In administrative databases and registries, nonwhite patients have been 
shown to be less likely to undergo invasive procedures and to have higher rates of 
adverse cardiac events. We sought to determine the association between race and out- 
come in patients with UNNSTEMI receiving modern therapy in a clinicai trial. 
Methods & Results: Of 2220 patients in TACTICS-TIM118, 498 were nonwhite (22.4%). 
Alt patients received aspirin, heparin, and upstream tirofiban and were randomized to 
invasive (INV) vs. conservative (CONS) management. In a Cox proportional hazards 
model that adjusted for confounders (including age, sex, cardiac risk factors, prior car- 
diac disease, ST deviation, and treponin elevation), nonwhite patients were at signifi- 
cantly increased risk for the composite endpoint of death, MI, or rehospitalization for ACS 
[hazard ratio (HR) 1.34, p=0.026]. When stratified by randomized treatment assignment, 
in the CONS arm there was no difference in outcome (HR for nonwhite patients 1.14, 
p=0.5), but in the INV arm nonwhite patients were at significantly higher risk (HR=1.70, 
p=0.005). Inclusion of angiographic extent of CAD and LVEF into the Cox model for 
patients in the INV arm did not diminish the increased risk associated with nonwhite race 
(HR=1.88, p=0.006), 
Conclusion: In UNNSTEMI, nonwhite patients assigned to invasive therapy are at sig- 
nificantly higher risk for death and ischemic complications. The reasons for this disparity 
are unclear and warrant further exploration. 
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840-2 HIV Disease and Acute Coronary Syndromes 
Randv B. Gould, Nioole B. Pearlstein, Mary C. De Voe, John T. Coppola, Frederick P. 
Siega[, John A. Ambrose, Saint Vincent Catholic Medical Centers of New York - 
Manhattan Division, New York, New York. 
Background: Sporadic cases have been reported of the association between HIV dis- 
ease and acute myocardial infarction. There are no large series and the response to 
interventional techniques is unknown. Our hospital center is a large referral base for HIV 
840-3 Benef i t  o f  Invasive Strategy for Women With Acute 
Coronary Syndromes: Observations From the TACTICS- 
TIMI 18 Trial 
Ruchira Glaser, Howard C. Herrmann, Sabina A. Murphy, Laura A. Demopoulos, Peter 
M. DiBattiste, Christopher P. Cannon, Eugene Braunwald, University of Pennsylvania 
Medical Center, Philade/phia, Pennsylvania, Brigham and Women's Hospital, Boston, 
Massachusetts. 
Background: Women with acute coronary syndromes (ACS) in the FRISC II trial had a 
worse outcome with invasive (INV) versus conservative (CON) management. However, 
this and other studies of management in ACS were performed before widespread use of 
glycopretein lib/Ilia inhibitors and stents. 
Methods: We compared the baseline characteristics and primary endpoint (death, MI, 
rehospitalization for ACS by 6 months) of 757 women and 1463 men treated with 
tirofiban and randomized to INV versus CON strategy in the TACTICS-TIM118 study. 
Results: Women were older, smoked less, and had less prior MI and coronary artery 
bypass grafting (CABG). Women presented less often with elevated cardiac markers, but 
there was no difference between men and women in TIMI risk score. Angiography and 
intervention rates were similar, but women had less severe CAD, including no critical 
lesions in 17% vs 9% of men (p<0.001). CABG rates were lower in women(15% vs 22% 
of men, p=0.003), but 30-day surgical mortality rates were similar. Finally, women and 
men had similar benefit from an early INV strategy (interaction p for gender = 0.6). The 
benefit was greatest in women with elevated troponin (primary endpoint of 18.6% vs 
29.0% in INV and CON arms, respectively, p=0.03) (see figure). 
Conclusions: Women with ACS had more risk factors than men and similar TIMI risk 
scores, but had less severe CAD. The benefit of tirofiban combined with an early INV 
strategy was similar in women and men, and enhanced in women presenting with ele- 
vated troponin T levels. 
~4H 
9:15 a.m. 
840-4 Dramatic Increase in 30-Day Morta l i ty  in Diabetic 
Patients With Non-ST Segment Elevation Acute 
Coronary Syndromes 
Marco Roffi. Leslie Cho, Deepak L Bhatt, Jennifer A. White, David J. Molitemo, Robed 
A. Harringtoo, Eric J. Topoi, The Cleveland Clinic Foundation, Cleveland, Ohio, Duke 
Clinical Research Institute, Durham, North Carolina. 
Background: Limited data. are available on outcome of diabetic patients presenting with 
non-ST-segment elevation acute coronary syndromes. Methods: We performed a 
pooled analysis of 4 glycoprotein nb/llla inhibitor-acute coronary syndrome tnals, PARA- 
GON A, PARAGON B, PURSUIT, and GUSTO IV, and addressed the impact of diabetes 
on 30-day mortality. Results: The Kaplan-Meier curves for 30-day mortality in diabetics 
and nondiabetics are shown in the Figure. Multivariate analysis demonstrated that diabe- 
tes was an independent predictor of mortality in the overall study population (hazard ratio 
1 38, p<0.001). Subgroup analysis among diabetic patients demonstrated following 30- 
day mortality rates: 7.7% for age >65 years vs. 2.7% for age ~ 65 years (p<0.001); 6.5% 
for insulin-dependent vs. 5.1% for non-insulin-dependent (p<0.037); 12.6% for creatinine 
>1.5 mg/dt vs. 4.8% for croatinine _< 1.5 rag/all (p<0.001). In a multivariate regression 
model, reduced renal function, ST-segment depression on ECG, insulin dependent dia- 
betes, and history of congestive heart failure, were all significant independent predictors 
